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a  b  s  t  r  a  c  t
Background: TB patients co-infected with HIV have worse treatment outcomes than non-
coinfected patients. How clinical characteristics of TB and socioeconomic characteristics
inﬂuence these outcomes is poorly understood. Here, we use polytomous regression anal-
ysis  to identify clinical and epidemiological characteristics associated with unfavorable
treatment outcomes among TB-HIV co-infected patients in Brazil.
Methods: TB-HIV cases reported in the Brazilian information system (SINAN) between Jan-
uary  1, 2001 and December 31, 2011 were identiﬁed and categorized by TB treatment outcome
(cure, default, death, and development of MDR TB). We  modeled treatment outcome as a
function of clinical characteristics of TB and patient socioeconomic characteristics by poly-Logistic regression tomous regression analysis. For each treatment outcome, we used cure as the reference
outcome.Results: Between 2001 and 2011, 990,017 cases of TB were reported in SINAN, of which 93,147
(9.4%) were HIV co-infected. Patients aged 15–19 (OR = 2.86; 95% CI: 2.09–3.91) and 20–39 years
old (OR = 2.30; 95% CI: 1.81–2.92) were more likely to default on TB treatment than those aged
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0–14 years old. In contrast, patients aged ≥60 years were more likely to die from TB (OR = 2.22;
95%  CI: 1.43–3.44) or other causes (OR = 2.86; 95% CI: 2.14–3.83). Black patients were more
likely to default on TB treatment (OR = 1.33; 95% CI: 1.22–1.44) and die from TB (OR = 1.50;
95%  CI: 1.29–1.74). Finally, alcoholism was associated with all unfavorable outcomes: default
(OR  = 1.94; 95% CI: 1.73–2.17), death due to TB (OR = 1.46; 95% CI: 1.25–1.71), death due to other
causes (OR = 1.38; 95% CI: 1.21–1.57) and MDR-TB (OR = 2.29; 95% CI: 1.46–3.58).
Conclusions: Socio-economic vulnerability has a signiﬁcant effect on treatment outcomes
among TB-HIV co-infected patients in Brazil. Enhancing social support, incorporation of
alcohol abuse screening and counseling into current TB surveillance programs and target-
ing  interventions to speciﬁc age groups are interventions that could improve treatment
outcomes.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is




































isease caused by co-infection with Mycobacterium tuberculo-
is and Human Immunodeﬁciency Virus (TB-HIV) is a major
lobal health problem.1 In Brazil, which is one of 22 high TB
urden countries in the world, HIV prevalence among adults
as  estimated to be 0.6% between 2000 and 2006.2 A 2014 study
ased on the Brazilian National Surveillance System (SINAN)
eported the prevalence of TB-HIV co-infection to be 19%.3
his study reported poor TB treatment outcomes in TB-HIV
atients,3 similar to other studies.4–11
Most prior studies of tuberculosis (TB) treatment out-
omes in co-infected patients in Brazil examined dichotomous
utcomes such as cure versus default or cure versus non-
ure.7–11 None examined polytomous treatment outcomes,
istinguishing between all possible outcomes present in the
otiﬁcation System (cure, default, death from TB, MDR-
B, and death from other causes) of SINAN among TB-HIV
atients.4–11 This type of analysis provides a more  detailed
nderstanding of the inﬂuence of clinical and social char-
cteristics on all TB treatment outcomes.12 Identiﬁcation of
B-HIV patients who are more  likely to have poor treatment
utcomes is essential for the development of targeted inter-
entions to improve treatment outcomes in this at-risk group.
uilding on the 2014 study cited above,3 which compared TB-
IV patients with a TB only group covering a 5-year period,
e performed a polytomous regression analysis to identify
linical and epidemiological characteristics associated with




 cross-sectional study design utilizing the Brazilian national
B reporting system (SINAN/TB) database was conducted.
INAN was developed in the early 1990s to collect and process
ata on disease notiﬁcations throughout the country. SINAN
eports only conﬁrmed cases and it is the primary informationlicenses/by-nc-nd/4.0/).
system from which data are extracted for epidemiological
analyses using secondary data in Brazil.13
Study  population
The study population was comprised of all TB cases with
HIV infection reported in Brazil between January 1, 2001
and December 31, 2011. TB cases were deﬁned as patients
with a conﬁrmed bacteriological diagnosis (smear or culture-
positive) or by a combination of clinical and epidemiological
data with results of diagnostic tests (smear and/or culture
and/or histopathology.14
A patient was considered HIV infected when a screen-
ing test by enzyme-linked immunosorbent assay (ELISA)
tested positive, followed by a conﬁrmatory western blot
test.15
Patients were classiﬁed into ﬁve (5) groups by treatment
outcome: cure (completed treatment with at least two  sub-
sequent negative smear examinations), default (those that
did not attend regular appointments for more  than 30 days),
death by TB,  other cause of death (died during TB treatment
of another cause), and MDR-TB (multidrug-resistant tuber-
culosis). Patients who initially were thought to have TB but
were subsequently found to have a different diagnosis were
excluded from the analysis.
Variables
The following socio-demographic covariates were extracted
from SINAN: age group (<20 years, 20–39 years, 40–59 years,
and ≥60 years), gender, skin color (white, black, brown,
and other), education (illiterate, 1–3 years of schooling,
4–7 years, ≥8 years, and not applicable for children less
than 6 years old), area of residence (urban, rural, or peri-
urban) and whether the individual was institutionalized
(prison/shelter/orphanage/mental hospital/others). The pres-
ence or absence of the following comorbidities was also
determined: diabetes, alcoholism and AIDS.Covariates related to the characteristics of tuberculosis
and its treatment were also obtained. These included: type
of entry in SINAN (new TB case: no prior TB diagnosis;
relapse – completed a previous TB treatment; return after
i s . 2 0164  b r a z j i n f e c t d 
default: individuals that defaulted from a previous TB treat-
ment regimen and returned to continue treatment), site of
TB at presentation (pulmonary, extra-pulmonary, pulmonary
and extra-pulmonary), tuberculin skin test result, existence
of chest X-ray suspicious for TB, result of initial sputum
smear test, result of initial culture examination and second
month smear, result of initial histopathological examina-
tion, and whether they received directly observed therapy
(DOT).
Data  analysis  and  statistics
Pearson’s chi-square test was used to compare proportions
between the treatment outcome groups. Variables associated
with the outcome of interest (p ≤ 0.05) were included in the
hierarchical multinomial logistic regression model.
We performed polytomous regression analysis with out-
come category as the dependent variable.12 For each possible
outcome (default, death from TB, development of MDR-TB,
and death from other case) the reference outcome was cure.
The present model was based on a conceptual framework
for social determinants of TB in which independent variables
are grouped into ﬁve levels: socio-demographic (Level 1), envi-
ronmental (Level 2), previous comorbidities (Level 3), clinical
features of TB (Level 4), and type of entry in SINAN and DOT
16(Level 5). At each level of analysis, those covariates associ-
ated with the outcome (p ≤ 0.05) were retained in the model.
All our analyses were conducted with Stata, version 13.0 (Stata
Corp, College Station, TX, USA).
A total of 990,017 cases were re
93,147 TB cas
HIV s
24,852 cases were excluded due:
transferred- 1898 (7.7%) did
not complete “treatment outcome”
field- 14,496 (58.3%) excluded








Fig. 1 – Study ﬂow diagram for selection 1 7;2  1(2):162–170
Ethics  statement
The databases were obtained under the rules for release of
the Secretariat of Health Surveillance and Health Care Depart-
ment of the Ministry of Health, ensuring the conﬁdentiality
and nondisclosure of individual identiﬁers. The Federal Uni-
versity of Espirito Santo (UFES) Institutional Review Board
approved the study design by registration number 242,831.
Results
Between 2001 and 2011, 990,017 cases of TB were reported
in SINAN, of which 93,147 (9.4%) were HIV co-infected
(Fig. 1). Because of missing information on TB treatment out-
come, 24,852 were excluded. Therefore, 68,295 patients were
included in our analysis.
The results of univariate analyses of socio-demographic
and clinical characteristics by treatment outcome are shown
in Tables 1 and 2. The proportions of all socio-demographic
and clinical characteristics examined varied signiﬁcantly
between treatment outcome groups. The hierarchical poly-
tomous regression model (Table 3) showed that default was
more  likely in individuals aged 15–19 years old (OR = 2.9,
95% CI 2.12–3.96), blacks (OR = 1.33, 95% CI 1.22–1.44), institu-
tionalized persons (OR = 2.92, 95% CI 1.11–7.69), and persons
with alcohol dependence (OR = 1.91, 95% CI 1.70–2.13). In
addition, default was more  likely to occur in persons diag-
nosed with AIDS (OR = 1.53, 95% CI 1.31–1.80), those diagnosed
ported in SINAN between 2001 and 2011
es among patients with
tatus positive









 of patients included in our study.
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Table 1 – Distribution of socio-demographic characteristics and clinical history among TB-HIV cases by treatment
outcome. Brazil, 2001–2011.
Characteristics Outcome
Cure n (%) Default n (%) Death due to TB n (%) Death due to other causes n (%) MDR-TBa n (%)
Gender (n = 82,776)b
Female 10,745 (28.70) 3909 (29.95) 907 (30.70) 4310 (29.44) 63 (31.19)
Male 26,692 (71.30) 9141 (70.05) 2047 (69.30) 10,329 (70.56) 139 (69.08)
Age, years (n = 82,789)b
0–14 897 (2.40) 155 (1.19) 39 (1.32) 157 (1.07) 1 (0.50)
15–19 506 (1.35) 247 (1.89) 39 (1.32) 123 (0.84) 4 (1.98)
20–39 22,313 (59.59) 9116 (69.84) 1551 (52.51) 8167 (55.78) 119 (58.91)
40–59 12,785 (34.14) 3398 (26.03) 1179 (39.91) 5613 (38.34) 73 (36.14)
≥60 944 (2.52) 137 (1.05) 146 (4.94) 581 (3.97) 5 (2.48)
Skin color (n = 57,577)b
White 13,372 (52.79) 4231 (48.50) 969 (36.59) 5068 (53.57) 100 (53.76)
Black 3732 (14.73) 1610 (18.46) 419 (15.82) 1487 (15.72) 34 (18.28)
Brown 7937 (31.33) 2797 (32.06) 1228 (46.37) 2810 (29.70) 51 (27.42)
Other 289 (1.14) 85 (0.97) 32 (1.21) 95 (1.00) 1 (0.54)
School level, years (n = 52,366)b
Illiterate 4788 (18.95) 1916 (22.59) 464 (25.88) 1722 (21.45) 34 (19.21)
1–3 1015 (4.02) 383 (4.52) 209 (11.66) 326 (4.06) 14 (7.91)
4–7 10,386 (41.10) 3806 (44.88) 513 (28.61) 3555 (44.28) 87 (49.15)
≥8 8043 (31.83) 2159 (25.46) 430 (23.98) 2186 (27.23) 34 (19.21)
Not applicablec 1039 (4.11) 216 (2.55) 177 (9.87) 239 (2.98) 8 (4.52)
Area of residence (n = 54,463)b
Urban 22,422 (95.70) 8035 (97.28) 2465 (95.91) 8402 (96.52) 186 (97.38)
Rural 885 (3.78) 198 (2.40) 89 (3.46) 264 (3.03) 4 (2.09)
Periurban 123 (0.52) 27 (0.33) 16 (0.62) 39 (0.45) 1 (0.52)
Institutionalized (n = 37,220)b
No 12,686 (88.33) 4714 (88.69) 2079 (90.39) 4729 (89.67) 123 (87.86)
Prison 1204 (8.38) 322 (6.06) 105 (4.57) 343 (6.50) 11 (7.86)
Shelter 16 (0.11) 12 (0.23) 5 (0.22) 11 (0.21) 1 (0.71)
Orphanage 34 (0.24) 10 (0.19) 6 (0.26) 9 (0.17) 0
Mental hospital 22 (0.15) 15 (0.28) 4 (0.17) 5 (0.09) 1 (0.71)
Other 400 (2.79) 242 (4.55) 101 (4.39) 177 (3.36) 4 (2.86)
Alcoholism (n = 40,838)b
No 14,173 (84.99) 4667 (76.70) 1831 (79.54) 5089 (82.05) 94 (68.61)
Yes 2504 (15.01) 1418 (23.30) 471 (20.46) 1113 (17.95) 43 (31.39)
Diabetes (n = 40,240)b
No 15,826 (96.99) 5817 (98.29) 2261 (97.37) 5972 (97.26) 127 (96.95)
Yes 491 (3.01) 101 (1.71) 61 (2.63) 168 (2.74) 4 (3.05)
AIDS (n = 74,396)b
No 1633 (4.99) 397 (3.41) 119 (4.18) 285 (2.11) 14 (7.91)
Yes 31,123 (95.01) 11,261 (96.59) 2731 (95.82) 13,240 (97.89) 163 (92.09)
a MDR-TB, multidrug-resistant tuberculosis.
b P < 0.001.








rith pulmonary and extra-pulmonary TB simultaneously
OR = 1.21, 95% CI 1.01–1.46), individuals with positive cul-
ures (OR = 1.44, 95% CI 1.11–1.86), notiﬁcation in SINAN as a
elapse (OR = 1.30, 95% CI 1.08–1.57) or as a return after default
OR = 5.13, 95% CI 4.36–6.02).
TB-HIV patients who  died due to TB were more  likely to be
ver 60 years old (OR = 2.18, 95% CI 1.41–3.39), black (OR = 1.48,
5% CI 1.27–1.71) or brown (OR = 2.17, 95% CI 1.94–2.43), and
eport alcoholism (OR = 1.48, 95% CI 1.26–1.72). In addition,those who died due to TB were more  likely to be diag-
nosed with AIDS (OR = 2.05, 95% CI 1.62–2.61), have pulmonary
and extra-pulmonary TB simultaneously (OR = 1.68, 95% CI
1.30–2.22), and return after default (OR = 1.81, 95% CI 1.33–2.48).
Death due to TB was less likely in patients with ≥8 years of
schooling (OR = 0.68, 95% CI 0.60–0.78) and patients receiving
DOT (OR = 0.75, 95% CI 0.61–0.91).
Regarding death due to other causes, the odds were higher
for persons aged 40–59 (OR = 2.08, 95% CI 1.61–2.67), persons
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Table 2 – Distribution of clinical characteristics among TB-HIV cases by treatment outcome. Brazil, 2001–2011.
Characteristics Outcome
Cure n (%) Default n (%) Death due to TB n (%) Death due to other causes n (%) MDR-TB n (%)
Type of entry (n = 82,791)b
New case 29,462 (78.68) 8080 (61.90) 2153 (72.88) 11,390 (77.80) 56 (27.72)
Relapse 3418 (9.13) 1231 (9.43) 221 (7.48) 1239 (8.46) 55 (27.23)
Return after default 2500 (6.68) 3132 (23.99) 298 (10.09) 1319 (9.01) 50 (24.75)
Unknown 190 (0.51) 88 (0.67) 58 (1.96) 187 (1.28) 1 (0.50)
Transferred 1875 (5.01) 522 (4.00) 224 (7.58) 506 (3.46) 40 (19.80)
Tuberculin skin test (n = 55,302)b
No reaction 3022 (12.73) 763 (9.06) 302 (11.75) 968 (10.91) 9 (4.52)
Weak reaction 600 (2.53) 144 (1.71) 30 (1.17) 127 (1.43) 0
Strong reaction 3230 (13.61) 840 (9.98) 74 (2.88) 304 (3.42) 10 (5.03)
Not performed 16,887 (71.14) 6671 (79.25) 2165 (84.21) 7477 (84.24) 180 (90.45)
TB form (n = 82,786)b
Pulmonary 23,494 (62.74) 8734 (66.91) 1931 (65.37) 8437 (57.65) 169 (83.66)
Extra-pulmonary 10,248 (27.37) 2812 (21.54) 596 (20.18) 3929 (26.84) 14 (6.93)
Pulmonary + extra-pulmonary 3703 (9.89) 1507 (11.55) 427 (14.45) 2270 (15.51) 19 (9.41)
Initial sputum smear (n = 82,791)b
Negative 12,479 (33.33) 3974 (30.45) 928 (31.42) 4702 (32.12) 35 (17.33)
Positive 13,799 (36.85) 5264 (40.33) 1004 (33.99) 4574 (31.24) 145 (71.78)
Not performed 11,167 (29.82) 3815 (29.23) 1022 (34.60) 5365 (36.64) 22 (10.89)
Sputum smear 2nd month (n = 30,199)b
Negative 3358 (28.97) 1036 (23.83) 554 (23.65) 985 (25.14) 26 (18.71)
Positive 3152 (27.19) 1208 (27.78) 469 (20.03) 683 (17.43) 69 (49.64)
Not performed 5081 (43.84) 2104 (48.39) 1319 (56.32) 2250 (57.43) 44 (31.65)
Sputum culture (n = 82,790)b
Negative 3447 (9.21) 969 (7.42) 143 (4.84) 995 (6.80) 10 (4.95)
Positive 4696 (12.54) 1796 (13.76) 233 (7.89) 1290 (8.81) 97 (48.02)
Result not available 2707 (7.23) 1133 (8.68) 260 (8.80) 1133 (7.74) 23 (11.39)
Not performed 26,594 (71.02) 9155 (70.14) 2318 (78.47) 11,223 (76.65) 72 (35.64)
X-ray suggestive of TB (n = 77,258)b
Negative 4586 (13.04) 1262 (10.37) 240 (8.50) 1563 (11.77) 8 (4.02)
Suspicious of TB 26,557 (75.52) 9480 (77.92) 2321 (82.19) 10,349 (77.96) 169 (84.92)
Not performed 4022 (11.44) 1425 (11.71) 263 (9.31) 1363 (10.27) 22 (11.06)
Histopathological (n = 74,040)b
AFB-positive 2971 (8.90) 887 (7.72) 200 (7.11) 907 (7.15) 10 (5.03)
Suggestive of TB 2995 (8.97) 715 (6.22) 133 (4.73) 643 (5.07) 7 (3.52)
Not suggestive of TB 440 (1.32) 140 (1.22) 23 (0.82) 186 (1.47) 1 (0.50)
Result not available 852 (2.55) 284 (2.47) 117 (4.16) 333 (2.62) 3 (1.51)
Not performed 26,132 (78.26) 9461 (82.36) 2338 (83.17) 10,623 (83.70) 178 (89.45)
DOTd (n = 70,034)b
No 23,921 (72.71) 8601 (77.04) 1765 (69.03) 8813 (74.18) 114 (57.58)
Yes 8979 (27.29) 2564 (22.96) 792 (30.97) 3067 (25.82) 84 (42.42)
a MDR-TB, multidrug-resistant tuberculosis.
b P < 0.001.
c AFB, acid-fast bacilli.
d DOT, directly observed therapy.
aged ≥60 (OR = 2.85, 95% CI 2.13–3.81), persons with alcohol
dependence (OR = 1.49, 95% CI 1.23–1.58) and those diagnosed
with AIDS (OR = 2.47, 95% CI 2.03–3.00). Diagnosis with of MDR-
TB in TB-HIV patients was more  likely when alcoholism was
reported (OR = 2.23, 95% CI 1.44–3.45), the initial sputum smear
was positive (OR = 2.52, 95% CI 1.29–4.92), and also with posi-
tive smear test at the second month of treatment (OR = 2.28,
95% CI 1.28–4.06). In addition, those who relapsed (OR = 7.76,
95% CI 4.18–14.43) or returned after default (OR= 10.25, 95% CI
5.44–19.34) had increased risk of developing MDR-TB.Discussion
Tuberculosis remains a major public health concern world-
wide and in Brazil, driven in part by TB-HIV co-infection.3 We
found that the socio-demographic characteristics most asso-
ciated with poor TB treatment outcomes were age (15–19 years
old and ≥60 years old), alcohol use, homelessness, less edu-
cation, and non-white race. The clinical factors associated
with poor TB treatment outcomes were resuming treatment
after failing a previous regimen (either relapse or return after
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Table 3 – Multinomial logistic regression with a hierarchical model of socio-demographic and clinical covariates
associated with tuberculosis treatment outcomes in patients with HIV status positive. Brazil, 2001–2011.
Characteristics Default Death due to TB Death due to other causes MDR-TBa
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Level 1
Gender
Female Ref Ref Ref Ref
Male 0.94 (0.89–1.01) 0.92 (0.83–1.03) 1.02 (0.96–1.09) 0.82 (0.60–1.13)
Age, years
0–14 Ref  Ref Ref Ref
15–19 2.86 (2.09–3.91) 1.67  (0.99–2.82) 1.20 (0.82–1.77) 5.22 (0.58–47.19)
20–39 2.30 (1.81–2.92) 1.29 (0.88–1.87) 1.86 (1.45–2.39) 3.49 (0.48–25.24)
40–59 1.42 (1.11–1.81) 1.67 (1.15–2.44) 2.09 (1.62–2.69) 4.09 (0.56–29.76)
≥60 0.71 (0.50–1.00) 2.22 (1.43–3.44) 2.86 (2.14–3.83) 3.13 (0.34–28.26)
Race
White Ref Ref Ref Ref
Black 1.33 (1.22–1.44) 1.50 (1.29–1.74) 1.05 (0.96–1.14) 0.99 (0.65–1.50)
Browns 1.08 (1.01–1.15) 2.19 (1.96–2.45) 0.94 (0.88–1.01) 0.83 (0.58–1.19)
Other 0.90 (0.67–1.20) 1.72 (1.12–2.63) 0.89 (0.67–1.19) 0.46 (0.06–3.33)
School level, years
Illiterate Ref Ref Ref Ref
1–3 0.91 (0.79–1.03) 2.00 (1.68–2.40) 0.89 (0.77–1.02) 1.66 (0.87–3.17)
4–7 0.89 (0.82–0.95) 0.86 (0.75–0.98) 1.01 (0.93–1.09) 1.75 (1.16–2.64)
≥8 0.68 (0.63–0.74) 0.82 (0.71–0.94) 0.78 (0.71–0.84) 0.78 (0.47–1.28)
Not applicable 0.51 (0.43–0.59) 1.69 (1.40–2.05) 0.65 (0.56–0.76) 1.02 (0.47–2.23)
Level 2
Area of residence
Urban Ref Ref Ref Ref
Rural 0.53 (0.41–0.68) 0.88 (0.67–1.15) 0.53 (0.40–0.69) 0.53 (0.16–1.69)
Periurban 0.68 (0.36–1.29) 0.90 (0.43–1.93) 0.95 (0.52–1.73) 1.38 (0.18–10.16))
Institutionalization
No Ref Ref Ref Ref
Prison 0.80 (0.67–0.96) 0.65 (0.48–0.86) 0.92 (0.76–1.12) 1.51 (0.79–2.87)
Shelter 2.88 (1.10–7.52) 1.28 (0.27–5.98) 1.84 (0.61–5.52) –
Orphanage 1.09 (0.48–2.49) 1.05 (0.36–3.09) 1.29 (0.54–3.04) –
Mental hospital 1.67 (0.71–3.92) 1.24 (0.35–4.34) 0.51 (0.11–2.26) 5.24 (0.70–42.47)
Other 1.53 (1.23–1.89) 1.34 (1.00–1.78) 1.37 (1.08–1.75) 1.28 (0.46–3.52)
Level 3
Diabetes
No Ref Ref Ref Ref
Yes 0.63 (0.45–0.88) 0.68 (0.46–1.01) 0.80 (0.59–1.08) 0.89 (0.27–2.88)
Alcoholism
No Ref Ref Ref Ref
Yes 1.94 (1.73–2.17) 1.46 (1.25–1.71) 1.38 (1.21–1.57) 2.29 (1.46–3.58)
AIDS
No Ref Ref Ref Ref
Yes 1.44 (1.21–1.70) 2.04 (1.57–2.65) 2.72 (2.17–3.42) 1.04 (0.55–1.96)
Level 4
TB form
Pulmonary Ref Ref Ref Ref
Extra-pulmonary 0.75 (0.64–0.87) 0.75 (0.61–0.93) 0.92 (0.78–1.07) 0.75 (0.27–2.03)
Pulmonary + extra-pulmonary 1.10 (0.94–1.30) 1.58 (1.30–1.92) 1.77 (1.51–2.08) 1.34 (0.72–2.50)
Tuberculin skin test
No reaction Ref Ref Ref Ref
Weak reaction 0.96 (0.64–1.42) 0.48 (0.26–0.89) 0.88 (0.60–1.29) –
Strong reaction 1.09 (0.89–1.35) 0.24 (0.17–0.35) 0.32 (0.25–0.43) 0.86 (0.27–2.74)
Not performed 1.65 (1.40–1.95) 1.37 (1.13–1.65) 1.29 (1.11–1.51) 2.05 (0.87–4.82)
Initial sputum smear
Negative Ref Ref Ref Ref
Positive 0.97 (0.82–1.15) 0.77 (0.62–0.96) 0.86 (0.72–1.04) 1.66 (0.80–3.46)
Not performed 0.84 (0.70–1.01) 0.79 (0.62–1.01) 0.93 (0.76–1.13) 0.83 (0.30–2.31)
X-ray
Negative Ref Ref Ref Ref
Suspicious of TB 0.93 (0.78–1.13) 1.09 (0.84–1.41) 0.93 (0.76–1.11) 0.82 (0.30–2.22)
Not performed 1.02 (0.82–1.27) 0.69 (0.49–0.96) 0.86 (0.68–1.09) 0.88 (0.28–2.76)
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Table 3 – (Continued)
Characteristics Default Death due to TB Death due to other causes MDR-TBa
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Histopathological examination
AFB-positiveb Ref Ref Ref Ref
Suggestive of TB 0.89 (0.70–1.14) 0.59 (0.40–0.86) 0.59 (0.45–0.77) 0.45 (0.05–3.87)
Not suggestive of TB 0.99 (0.63–1.57) 0.49 (0.22–1.10) 0.94 (0.59–1.51) 1.51 (0.17–13.17)
Result not available 1.25 (0.92–1.70) 1.31 (0.88–1.95) 0.91 (0.65–1.28) 2.08 (0.40–10.73)
Not performed 1.06 (0.89–1.25) 1.18 (0.93–1.50) 1.08 (0.91–1.29) 2.15 (0.91–5.08)
Sputum culture
Negative Ref Ref Ref Ref
Positive 1.50 (1.18–1.91) 1.19 (0.83–1.69) 1.02 (0.77–1.36) 6.0 (2.35–15.49)
Result not available 1.55 (1.21–1.98) 1.52 (1.08–2.14) 1.27 (0.96–1.68) 1.52 (0.52–4.49)
Not performed 1.18 (0.96–1.44) 1.44 (1.08–1.90) 1.55 (1.24–1.94) 0.41 (0.15–1.09)
Sputum smear 2nd month
Negative Ref Ref Ref Ref
Positive 1.09 (0.91–1.32) 0.95 (0.74–1.23) 0.76 (0.62–0.95) 1.20 (0.56–2.57)
Not performed 1.37 (1.15–1.63) 1.47 (1.17–1.84) 1.23 (1.02–1.48) 1.36 (0.63–2.94)
Level 5
Type of entry
New case Ref Ref Ref Ref
Relapse 1.27 (1.07–1.50) 0.78 (0.60–1.00) 1.08 (0.88–1.33) 6.47 (3.74–11.18)
Return after default 4.78 (4.13–5.55) 1.69 (1.34–2.12) 1.90 (1.54–2.36) 8.13 (4.59–14.43)
Unknown 1.45 (––) 3.67 (1.05–12.78) 2.21 (0.55–8.91) –
Transferred 1.06 (0.89–1.27) 0.99 (0.79–1.25) 0.80 (0.63–1.00) 3.41 (1.71–6.80)
DOTc
No Ref Ref Ref Ref
Yes 0.74 (0.67–0.83) 0.81 (0.70–0.94) 0.81 (0.71–0.93) 1.71 (1.10–2.64)
The values in bold were statistically signiﬁcant.
a MDR-TB, multidrug-resistant tuberculosis.
b AFB, acid-fast bacilli.
c DOT, directly observed therapy.
dropout), AIDS and site of TB infection (pulmonary and extra-
pulmonary TB simultaneously).
The rising rate of TB-HIV incidence found in our study may
be explained by higher rates of HIV testing among TB cases
observed from 2001 to 2011 in Brazil.17 The effect of age on
treatment outcomes that we  observed may be more  compli-
cated to clarify. Older age is a risk factor for mortality among
TB patients with and without HIV.18,19 It is also an independent
risk factor for infectious diseases, in part due to age-related
decreases in immunity.20 Age-related decreases in immunity
could thus explain both the increase in TB mortality as well
as increases in mortality from other causes.
The effect we  observed of alcohol on treatment outcomes
appears to be linked to age. In Brazil, younger TB-HIV patients
have higher rates of high-risk behaviors, including alcohol
use, smoking, and use of illicit drugs.21 In our study popula-
tion, the majority of patients with alcohol use were of younger
age (20–39 years old). Therefore, the higher rates of treatment
default we  observed may be attributable to these behaviors.
The effects of housing status, education and race are likely
to have a common explanation: low socioeconomic status
(SES). In the face of more  pressing matters (e.g. ﬁnancial and
food insecurity) and reduced access to services, persons with
low SES are less likely to prioritize TB care/treatment. It is
thus unsurprising that housing status, education, and race,
all of which are markers of SES, were associated with worse
TB treatment outcomes.22 A good example of the difﬁcultiesfaced by this group is that in some Brazilian cities, patients
are able to receive HAART (Highly Active Antiretroviral Ther-
apy) but not food vouchers or transportation subsidies. The
absence of the latter two services makes successful treatment
virtually impossible.3 The importance of access to services is
reinforced by our results in persons with diabetes mellitus and
in prisoners. Both of these groups had lower rates of treatment
default, possibly because of better, more  consistent contact
with the healthcare system.
Unsuccessful prior TB treatment had a signiﬁcant impact
on TB treatment outcomes, with patients who  relapsed and
patients who returned to treatment after default doing poorly.
These poor treatment outcomes were largely due to mycobac-
terial resistance that was a direct consequence of having been
exposed to incomplete treatment, which could have happened
multiple times. These patients had much higher rates of MDR-
TB and, as a result, poorer outcomes.
Finally, the associations we observed between AIDS and
site of TB infection with poorer treatment outcomes are
almost certainly linked. Higher levels of immunosuppression
increase the likelihood of extra-pulmonary or simultaneous
extra-pulmonary and pulmonary TB, all of which are more
difﬁcult to treat.23–27 Although we did not have access to CD4
counts and could not estimate the mean level of immunosup-
pression in patients with AIDS, this possibility seems to be the
likely explanation for poor outcomes in these groups.
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Although we  believe the results we  report here to be impor-
ant and clinically relevant, it is important to acknowledge a
rimary limitation of our analysis: there was a large amount
f missing data regarding treatment outcome. These missing
ata could have biased our risk estimates, resulting in under
r over estimation. To examine this possibility, we  repeated
ur analysis including these data and observed only a neg-
igible effect on our risk estimates (data not shown). Bias is
lways a concern with secondary data sources, but the SINAN
atabase has already served as a source for several other
obust population-based studies in Brazil.3,28,29 A second lim-
tation of our results is their generalizability. Whether the
ocial factors that are relevant in Brazil will also be relevant to
ther countries is unknown. However, each of the factors we
dentiﬁed is tied to poverty and while the speciﬁc factors may
ary from country to country, we  believe that the link between
overty and poorer TB-HIV treatment outcomes may remain
onsistent.
We  show here the signiﬁcant inﬂuence of socio-
emographic and clinical factors on treatment outcomes
n TB-HIV co-infected patients in Brazil. We  identify insufﬁ-
ient institutional support for the poor as a primary barrier
o achieving better TB-HIV treatment outcomes. New strate-
ies must be developed and implemented to mitigate these
ffects. One potential strategy is to have better coordination
etween TB and HIV control programs, through collaborative
B-HIV activities. These activities include: (1) HIV testing and
ounseling for patients with presumptive and diagnosed TB;
2) TB prevention through isoniazid and early antiretroviral
herapy. Another potential strategy to is to take advantage
f the Brazilian healthcare system’s existing structure of
ommunity healthcare workers to develop community-based
B treatment programs.30–34 Both of the strategies we pro-
ose focus on the healthcare system, but for them to be
ost effective they must be coupled with efforts to improve
atients’ social conditions. Providing food vouchers and
ransportation subsidies could help improve adherence to
oth TB and antiretroviral therapy. Similarly, given the strong
nﬂuence of alcohol, incorporation of screening instruments
uch as the Alcohol Use Disorder Identiﬁcation Test (AUDIT)
nd Screening and Brief Interventions into current TB surveil-
ance activities could improve treatment adherence.35,36
hese and other initiatives aimed at addressing patients’
ocial conditions could have a signiﬁcant impact on TB-HIV
reatment outcomes.
onclusions
he key factors driving unfavorable tuberculosis treatment
utcomes in TB-HIV co-infected patients in Brazil were age
15–19 years old and ≥60 years old), alcohol use, homeless-
ess, less education, non-white race, and the form of TB.
any  of these factors are markers of socio-economic vul-
erability. These ﬁndings have broad policy implications:
roviding better socio-economic support to patients is likely
he key to improving outcomes. There is a pressing need
o improve coordination between TB and HIV control pro-
rams. Speciﬁc initiatives could include the incorporation
f alcohol abuse screening and counseling into current TB
17;2 1(2):162–170 169
control programs, which could result in better treatment
outcomes.
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